ECSP045087A - Nueva formulación de jarabe de epinastina seco y acuoso - Google Patents
Nueva formulación de jarabe de epinastina seco y acuosoInfo
- Publication number
- ECSP045087A ECSP045087A EC2004005087A ECSP045087A ECSP045087A EC SP045087 A ECSP045087 A EC SP045087A EC 2004005087 A EC2004005087 A EC 2004005087A EC SP045087 A ECSP045087 A EC SP045087A EC SP045087 A ECSP045087 A EC SP045087A
- Authority
- EC
- Ecuador
- Prior art keywords
- epinastine
- syrup
- dry
- water
- new formulation
- Prior art date
Links
- WHWZLSFABNNENI-UHFFFAOYSA-N epinastine Chemical compound C1C2=CC=CC=C2C2CN=C(N)N2C2=CC=CC=C21 WHWZLSFABNNENI-UHFFFAOYSA-N 0.000 title abstract 4
- 229960003449 epinastine Drugs 0.000 title abstract 4
- 238000009472 formulation Methods 0.000 title abstract 3
- 239000000203 mixture Substances 0.000 title abstract 3
- 239000006188 syrup Substances 0.000 title abstract 2
- 235000020357 syrup Nutrition 0.000 title abstract 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 title abstract 2
- 208000002193 Pain Diseases 0.000 abstract 3
- 206010010741 Conjunctivitis Diseases 0.000 abstract 2
- 206010020751 Hypersensitivity Diseases 0.000 abstract 2
- 230000007815 allergy Effects 0.000 abstract 2
- 208000006673 asthma Diseases 0.000 abstract 2
- 206010006451 bronchitis Diseases 0.000 abstract 2
- 206010039083 rhinitis Diseases 0.000 abstract 2
- 208000000094 Chronic Pain Diseases 0.000 abstract 1
- 201000004624 Dermatitis Diseases 0.000 abstract 1
- 206010061218 Inflammation Diseases 0.000 abstract 1
- 208000019695 Migraine disease Diseases 0.000 abstract 1
- 239000012458 free base Substances 0.000 abstract 1
- 230000004054 inflammatory process Effects 0.000 abstract 1
- 206010027599 migraine Diseases 0.000 abstract 1
- 239000000843 powder Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Ophthalmology & Optometry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Rheumatology (AREA)
- Immunology (AREA)
- Otolaryngology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medical Preparation Storing Or Oral Administration Devices (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10152973A DE10152973A1 (de) | 2001-10-26 | 2001-10-26 | Neue trockene und wässrige Epinastin-Sirup-Formulierung |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ECSP045087A true ECSP045087A (es) | 2004-06-28 |
Family
ID=7703856
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EC2004005087A ECSP045087A (es) | 2001-10-26 | 2004-04-26 | Nueva formulación de jarabe de epinastina seco y acuoso |
Country Status (9)
| Country | Link |
|---|---|
| EP (1) | EP1448204A1 (ja) |
| JP (2) | JP4564749B2 (ja) |
| KR (1) | KR20050034619A (ja) |
| BR (1) | BR0213488A (ja) |
| CO (1) | CO5580751A2 (ja) |
| DE (1) | DE10152973A1 (ja) |
| EC (1) | ECSP045087A (ja) |
| MX (1) | MXPA04003772A (ja) |
| WO (1) | WO2003037350A1 (ja) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1452177A1 (en) * | 2003-02-27 | 2004-09-01 | Boehringer Ingelheim International GmbH | Pharmaceutical formulations comprising sodium laurylsulfate as bitterness masking agent |
| US20040247686A1 (en) * | 2003-04-04 | 2004-12-09 | Boehringer Ingelheim International Gmbh | Pharmaceutical compositions comprising epinastine for the treatment of skin diseases |
| EP1735001A2 (en) * | 2004-03-24 | 2006-12-27 | Boehringer Ingelheim International Gmbh | Pharmaceutical compositions for the treatment of skin diseases comprising a combination of epinastine and one or more additional minerals or one or more crude drugs |
| JP5132090B2 (ja) * | 2006-06-16 | 2013-01-30 | 東和薬品株式会社 | 塩酸エピナスチンドライシロップ剤 |
| CN105708840A (zh) * | 2014-12-01 | 2016-06-29 | 重庆安格龙翔医药科技有限公司 | 一种盐酸依匹斯汀组合物 |
| CN105708807B (zh) * | 2014-12-01 | 2018-11-27 | 重庆安格龙翔医药科技有限公司 | 一种盐酸依匹斯汀细粒剂的制备方法 |
| CN105708808B (zh) * | 2014-12-01 | 2018-11-27 | 重庆安格龙翔医药科技有限公司 | 一种盐酸依匹斯汀颗粒剂及其制备方法 |
| JP7599838B2 (ja) * | 2019-04-10 | 2024-12-16 | 参天製薬株式会社 | エピナスチン又はその塩を含有する水性医薬組成物 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3008944A1 (de) * | 1980-03-08 | 1981-09-24 | C.H. Boehringer Sohn, 6507 Ingelheim | Dibenzimidazoazepine, ihre herstellung und verwendung |
| EP0658340A1 (en) * | 1993-12-17 | 1995-06-21 | Unilever N.V. | Oral compositions |
| JPH0827034A (ja) * | 1994-07-14 | 1996-01-30 | Nikken Chem Co Ltd | エリスリトール含有内用液剤 |
| JPH0952849A (ja) * | 1995-06-06 | 1997-02-25 | Taisho Pharmaceut Co Ltd | 感冒剤用組成物 |
| DE19542281C2 (de) * | 1995-11-14 | 1997-12-04 | Boehringer Ingelheim Kg | Verwendung von Epinastin für die Behandlung der Migräne |
| JPH1045576A (ja) * | 1996-08-05 | 1998-02-17 | Taisho Pharmaceut Co Ltd | 鼻炎用内服薬 |
| EP1020193A4 (en) * | 1997-09-30 | 2006-05-24 | Daiichi Seiyaku Co | ORAL PREPARATION |
| JPH11302189A (ja) * | 1998-04-21 | 1999-11-02 | Taisho Pharmaceut Co Ltd | 感冒用組成物 |
| DK1138333T3 (da) * | 1999-10-12 | 2004-05-24 | Daiichi Suntory Pharma Co Ltd | Medicinske præparater til oral anvendelse |
-
2001
- 2001-10-26 DE DE10152973A patent/DE10152973A1/de not_active Withdrawn
-
2002
- 2002-10-08 MX MXPA04003772A patent/MXPA04003772A/es unknown
- 2002-10-08 EP EP02802290A patent/EP1448204A1/en not_active Withdrawn
- 2002-10-08 BR BR0213488-8A patent/BR0213488A/pt not_active Application Discontinuation
- 2002-10-08 KR KR1020047006205A patent/KR20050034619A/ko not_active Withdrawn
- 2002-10-08 WO PCT/EP2002/011250 patent/WO2003037350A1/en not_active Ceased
- 2002-10-08 JP JP2003539693A patent/JP4564749B2/ja not_active Expired - Lifetime
-
2004
- 2004-04-26 EC EC2004005087A patent/ECSP045087A/es unknown
- 2004-05-07 CO CO04042457A patent/CO5580751A2/es not_active Application Discontinuation
-
2010
- 2010-03-02 JP JP2010044902A patent/JP2010132702A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2005508364A (ja) | 2005-03-31 |
| JP4564749B2 (ja) | 2010-10-20 |
| BR0213488A (pt) | 2004-11-03 |
| DE10152973A1 (de) | 2003-05-08 |
| MXPA04003772A (es) | 2004-07-30 |
| KR20050034619A (ko) | 2005-04-14 |
| WO2003037350A1 (en) | 2003-05-08 |
| CO5580751A2 (es) | 2005-11-30 |
| EP1448204A1 (en) | 2004-08-25 |
| JP2010132702A (ja) | 2010-06-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR0314603A (pt) | Uso de inibidores da sìntese de citoquina para o tratamento de distúrbios de olhos secos | |
| CL2007002450A1 (es) | Forma polimorfica i del enantiomero levogiro o dextrogiro de modafinilo; su procedimiento de preparacion; y composicion farmaceutica que los comprende (divisional solicitud 2693-03). | |
| IL158559A0 (en) | Acne treatment | |
| EP1575536A4 (en) | TOPICAL USE OF COSMETIC COMPOSITION INFLATION AFTER APPLICATION | |
| DK1347955T3 (da) | Nye mandelsyrederivater og deres anvendelse som throbin-hæmmere | |
| ECSP045087A (es) | Nueva formulación de jarabe de epinastina seco y acuoso | |
| MX2009010761A (es) | Formas cristalinas de 6-[2-(metilcarbamoil)fenilsulfanil]-3-e-[2-( piridin-2-il)etenil]indzol adecuadas para el tratamiento del crecimiento celular anormal en mamiferos. | |
| DK1523335T3 (da) | Injicerbar depotformulering omfattende iloperidonkrystaller | |
| BR0111913A (pt) | Análogos de gabapentina para distúrbios do sono | |
| CR9723A (es) | Nueva forma cristalina de un derivado de piridazino[4,5-b] indol | |
| WO2004000293A3 (fr) | Utilisation de la taurine ou de derives pour le traitement de l'alopecie | |
| UY30591A1 (es) | Crema para bebidas | |
| AR054833A1 (es) | Formas de dosificacion de liberacion retardada oral altamemte biodisponibles de succinato de o-desmetilvenlafaxina | |
| IS7820A (is) | Samsetningar sem innihalda melatónín, musterisviðog bíótín | |
| NO20033959L (no) | Benzimidazoler som er nyttige i behandling av seksuell dysfunksjon | |
| PA8613001A1 (es) | Derivados de triazol sustituidos como antagonistas de oxitocina | |
| PA8562001A1 (es) | Brivudina estabilizada en formulaciones topicas | |
| AU2002243451A1 (en) | Use of catecholamine reuptake inhibitors to enhance memory | |
| MD4093B1 (ro) | Utilizare a compoziţiei farmaceutice topice cu conţinut de ambroxol | |
| IS6426A (is) | Píperasínómetýlbensamíð sem delta-ópíóíðviðtakagerandefni | |
| NO20024724L (no) | Profylaktisk og terapeutisk bruk av oltipraz som antifibrotisk og anticirrhotisk middel i leveren og enfarmasöytisk sammensetning som inneholder oltipraz | |
| IL189915A0 (en) | Use of inhibitors of the na+/h+exchanger, subtype 5 (nhe5), to improve memory retention | |
| PE20070117A1 (es) | Compuestos de n-(2,2-dimetilpropil)-6-{3-fluoro-5-[(3-isoxazolilamino)carbonil]-2-metilfenil}-3-pirimidinacarboxamida y procedimiento de preparacion | |
| AR041999A1 (es) | Composiciones farmaceuticas que contienen ambroxol y yoduro de isopropamida | |
| EP1349567A4 (en) | COMPOSITIONS WITH GANGLIOSIDES FOR USE IN THE TREATMENT OF SKIN DISEASES |